Physician profile
Joy Cheuvront
NPI 1609493352
$769.34
in general payments reported to CMS, 2019-2025
13 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $412 · 2024: $90.33 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $769.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $124.74 | 2023 | Uplizna |
| Lundbeck LLC | $113.74 | 2023-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $107.10 | 2023 | Ultomiris |
| Biogen, INC. | $100.00 | 2023 | Tysabri |
| Octapharma USA, INC. | $81.91 | 2024-2025 | Octagam Immune Globulin (Human), Panzyga |
| Takeda Pharmaceuticals U.S.A., INC. | $45.50 | 2025 | Cuvitru |
| Argenx US, INC. | $43.41 | 2024-2025 | Vyvgart Hytrulo |
| Grifols USA, LLC | $38.62 | 2025 | Gamunex-C |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.05 | 2023 | Spevigo |
| Janssen Biotech, INC. | $25.39 | 2025 | |
| Alnylam Pharmaceuticals INC. | $24.78 | 2025 | Givlaari |
| Genentech, INC. | $18.79 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $14.31 | 2024 | Fasenra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Cheuvront listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.